Developer docs
API playgroundTry for free, no card

Search company profiles

Pulse Biosciences

Full company profile

uuid00023rf

Namestring
Pulse Biosciences
Legal namestring
Pulse Biosciences, Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Pulse Biosciences is a clinical-stage bioelectric medicine company developing a proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology platform that delivers nanosecond-duration electrical pulses to create nanopores in cellular membranes, triggering regulated cell death while sparing adjacent noncellular tissue structures such as vessels, nerves, and connective tissue. The company's product portfolio is built around a shared nsPFA console generator and includes the FDA-cleared nPulse Vybrance Percutaneous Electrode System for soft tissue ablation (used in benign thyroid nodules), the investigational nsPFA 360 Catheter Endocardial Ablation System for catheter-based atrial fibrillation ablation, and the investigational nsPFA Cardiac Surgery Ablation System (cardiac clamp) for open concomitant surgical AF procedures. The lead cardiac program is supported by the NANOPULSE-AF IDE pivotal study planning enrollment of approximately 215 patients across up to 30 sites in the U.S. and Europe, alongside the parallel NANOCLAMP AF study, with clinical data showing 96% procedural success at 12 months and 1.7% serious adverse event rates in the European feasibility cohort.

The business operates a direct enterprise field sales model targeting hospitals, electrophysiology labs, and cardiac surgery centers, with demand generation concentrated at major medical conferences (Heart Rhythm Society, AF Symposium, NASIT) and physician key opinion leader networks. Revenue is generated through hardware sales of consoles, catheters, and electrodes, supplemented by clinical procedure revenue at treatment centers; full-year 2025 revenue was $350K and Q1 2026 revenue was $401K, reflecting the early commercial stage of the only FDA-cleared product. The company has integrated its catheter with Abbott's EnSite X and Johnson & Johnson's CARTO 3 electroanatomical mapping systems to fit into standard electrophysiology lab workflows. Capital structure is concentrated: majority shareholder Robert W. Duggan owns approximately 69% of outstanding shares following $115M of private placements in 2021 and 2023, a $60M rights offering in 2024, and a $13.3M insider ATM purchase in May 2026, with cash of $80.7M as of Q4 2025 against a $72.8M full-year GAAP net loss.

Short descriptiontext

Pulse Biosciences is a clinical-stage bioelectric medicine company developing proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for treating atrial fibrillation, benign thyroid nodules, and other soft tissue conditions, serving electrophysiologists, cardiac surgeons, and interventional endocrinologists.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHayward, United States
HQ citystring
Hayward
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pulsed field ablation, cardiac ablation devices, electrophysiology systems, surgical ablation clamps, thyroid nodule ablation
Industry1 code
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Ablation Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1nPulse/Vybrance System Sales
TypeHardware Sales
Description

Revenue generated from sale of nPulse ablation systems including consoles, catheters, and electrodes to healthcare providers and hospitals for clinical procedures and trials.

fool.com
2Clinical Procedure Revenue
TypeHardware Sales
Description

Revenue from medical procedures using nPulse technology at treatment centers. Q1 2026 reported $401,000 in revenue; Q4 2025 reported $264,000 primarily from Vybrance systems and electrodes.

fool.com
3At-the-Market Equity Offerings
TypeOne Time License
Description

Company raises capital through at-the-market equity offering programs. In May 2026, co-chairmen purchased $13.3 million of company stock through the ATM program managed by TD Securities.

fool.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1CellFX
Description

Brand name for the company's nsPFA technology platform used for cardiac applications.

pulsebiosciences.com
+3 more records
Core offering1 text field

Pulse Biosciences develops and commercializes medical devices based on its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. The company sells the FDA-cleared nPulse Vybrance Percutaneous Electrode System for soft tissue ablation and is developing investigational devices—the nsPFA 360 Catheter Endocardial Ablation System and the nsPFA Cardiac Surgical Clamp—for treating atrial fibrillation through catheter-based and open surgical approaches. All systems rely on a shared nsPFA Console generator that delivers nanosecond electrical pulses to induce regulated cell death while sparing noncellular tissue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 96% procedural success at 12 months follow-up for atrial fibrillation treatment
+6 more records
Product overview1 text field

Pulse Biosciences offers a platform-based product portfolio built around its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. The nPulse Vybrance Percutaneous Electrode System is FDA-cleared for soft tissue ablation in percutaneous and intraoperative procedures. The nsPFA 360 Catheter Endocardial Ablation System and nsPFA Cardiac Surgery Ablation System (nPulse Cardiac Clamp) are investigational devices for treating atrial fibrillation through catheter-based and surgical approaches respectively. All cardiac products share the nsPFA Console as the common generator platform, which delivers the underlying nanosecond pulsed field energy that enables cell-targeting ablation while sparing adjacent noncellular tissue structures.

Product and service4 records
1nPulse Vybrance Percutaneous Electrode System
CategoryPercutaneous soft tissue ablation system
Description

FDA-cleared percutaneous electrode system utilizing Nanosecond Pulsed Field Ablation (nsPFA) energy for ablation of soft tissue in percutaneous and intraoperative surgical procedures. It induces regulated cell death while sparing adjacent acellular tissue including vessels, nerves, and connective tissue, used for benign thyroid nodule ablation.

2nsPFA 360 Catheter Endocardial Ablation System
CategoryCardiac electrophysiology catheter ablation system
Description

Investigational cardiac catheter system for endocardial ablation during electrophysiology procedures, comprising the nsPFA Console and nsPFA 360 Catheter with integrated sensing electrodes, designed to create circumferential ablation for pulmonary vein isolation while sparing acellular tissue in atrial fibrillation treatment.

3nsPFA Cardiac Surgery Ablation System (nPulse Cardiac Clamp)
CategorySurgical cardiac ablation clamp system
Description

Investigational cardiac surgical clamp system using nsPFA technology for ablation during open concomitant surgical atrial fibrillation procedures. Available in 53mm or 65mm jaw lengths, designed to create continuous linear transmural ablations while minimizing damage to surrounding acellular tissue.

4nsPFA Console (Generator Platform)
CategoryCapital equipment generator platform
Description

Power generator platform that delivers Nanosecond Pulsed Field Ablation energy for the nPulse product family. Operated via integrated touch screen and foot pedal, the console generates nanosecond PFA energy designed to induce regulated cell death of treated cardiac tissue while shielding interconnected lab equipment.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-09
Description

Research collaboration to evaluate nPulse technology for treating thyroid cancers, with planned clinical study for papillary thyroid microcarcinoma treatment beginning early 2026. Preclinical studies on anaplastic thyroid carcinoma are ongoing. This collaboration extends the nsPFA platform into oncology applications.

2Abbott
Strategic tierCoreTypeTechnology or Integration
Description

nPulse Cardiac Catheter System is integrated with Abbott's EnSite X 3D electroanatomical mapping system for pulmonary vein isolation procedures. Integration enables procedural workflow combining nPulse ablation with Abbott's mapping technology.

investing.com
Strategic tierCoreTypeTechnology or Integration
Description

nsPFA 360 Catheter integrated with CARTO 3 Mapping System from Johnson & Johnson for live case demonstrations at HRS 2025. Integration enables combined ablation and mapping workflow for atrial fibrillation procedures.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston Scientific's FARAPULSE pulsed field ablation system is the leading commercial PFA catheter for atrial fibrillation, directly competing with Pulse Biosciences' nPulse 360 Catheter in the same EP lab workflow and AF indication.

2Johnson & Johnson (Biosense Webster)
TypeDirect peer
Description

Biosense Webster's CARTO 3 mapping and ThermoCool/Smart-Touch PFA catheters compete directly in AF ablation, and Pulse Biosciences' catheter is already integrated with CARTO 3, making J&J both a partner and a direct competitor.

3Abbott
TypeDirect peer
Description

Abbott's EnSite X mapping system and TactiFlex PFA catheter compete in EP ablation; Pulse Biosciences integrates with EnSite X, positioning Abbott as both a workflow partner and competitive incumbent.

TypeDirect peer
Description

Medtronic's PulseSelect and Affera-derived PFA systems target the same AF ablation market as Pulse Biosciences' nPulse 360, with a deep EP installed base and global commercial reach.

TypeDirect peer
Description

AtriCure is the dominant player in surgical AF ablation (the Isolator Synergy clamp and cryo devices) and is the closest direct competitor to Pulse Biosciences' nsPFA Cardiac Clamp in the open concomitant surgical AF setting.

TypeDirect peer
Description

AngioDynamics markets the NanoKnife irreversible electroporation system, the closest direct mechanistic peer to nsPFA, used for soft tissue ablation including prostate and pancreatic lesions, with overlap on the Vybrance non-cardiac indication.

TypeEmerging player
Description

Galvanize Therapeutics is a private pulsed electric field company developing EP and oncology ablation platforms, intersecting with both Pulse's cardiac catheter and soft tissue/oncology roadmaps as an emerging PFA competitor.

8Adagio Medical
TypeEmerging player
Description

Adagio Medical develops a cryo-PFA hybrid catheter for AF ablation, positioning it as a partial-overlap emerging competitor to Pulse's nPulse 360 in the paroxysmal and persistent AF EP market.

TypeEmerging player
Description

Penumbra has expanded from thrombectomy into the electrophysiology and PFA space through Lightning Flash and related catheter platforms, creating indirect competition with Pulse's cardiac ablation program.

10MicroPort Scientific
TypeRegional player
Description

MicroPort's EP division (formerly Cardiac Rhythmic Technologies and acquired assets) markets cardiac ablation products in Asia and Europe, representing a regional PFA/AF ablation competitor to Pulse's eventual global rollout.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pulse Biosciences

Cardiac Ablation Medical Devicespulsebiosciences.com

Pulse Biosciences is a clinical-stage bioelectric medicine company developing proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for treating atrial fibrillation, benign thyroid nodules, and other soft tissue conditions, serving electrophysiologists, cardiac surgeons, and interventional endocrinologists.

What Pulse Biosciences does

Pulse Biosciences is a clinical-stage bioelectric medicine company developing a proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology platform that delivers nanosecond-duration electrical pulses to create nanopores in cellular membranes, triggering regulated cell death while sparing adjacent noncellular tissue structures such as vessels, nerves, and connective tissue. The company's product portfolio is built around a shared nsPFA console generator and includes the FDA-cleared nPulse Vybrance Percutaneous Electrode System for soft tissue ablation (used in benign thyroid nodules), the investigational nsPFA 360 Catheter Endocardial Ablation System for catheter-based atrial fibrillation ablation, and the investigational nsPFA Cardiac Surgery Ablation System (cardiac clamp) for open concomitant surgical AF procedures. The lead cardiac program is supported by the NANOPULSE-AF IDE pivotal study planning enrollment of approximately 215 patients across up to 30 sites in the U.S. and Europe, alongside the parallel NANOCLAMP AF study, with clinical data showing 96% procedural success at 12 months and 1.7% serious adverse event rates in the European feasibility cohort.

The business operates a direct enterprise field sales model targeting hospitals, electrophysiology labs, and cardiac surgery centers, with demand generation concentrated at major medical conferences (Heart Rhythm Society, AF Symposium, NASIT) and physician key opinion leader networks. Revenue is generated through hardware sales of consoles, catheters, and electrodes, supplemented by clinical procedure revenue at treatment centers; full-year 2025 revenue was $350K and Q1 2026 revenue was $401K, reflecting the early commercial stage of the only FDA-cleared product. The company has integrated its catheter with Abbott's EnSite X and Johnson & Johnson's CARTO 3 electroanatomical mapping systems to fit into standard electrophysiology lab workflows. Capital structure is concentrated: majority shareholder Robert W. Duggan owns approximately 69% of outstanding shares following $115M of private placements in 2021 and 2023, a $60M rights offering in 2024, and a $13.3M insider ATM purchase in May 2026, with cash of $80.7M as of Q4 2025 against a $72.8M full-year GAAP net loss.

Pulse Biosciences firmographics

Firmographics
Name
Pulse Biosciences
Legal name
Pulse Biosciences, Inc.
Website
https://pulsebiosciences.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Pulse Biosciences is a clinical-stage bioelectric medicine company developing proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for treating atrial fibrillation, benign thyroid nodules, and other soft tissue conditions, serving electrophysiologists, cardiac surgeons, and interventional endocrinologists.
Ownership category
akta.pro rank

Pulse Biosciences industry classification

Industry
Product category
Cardiac Ablation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Pulsed field ablation
  • Cardiac ablation devices
  • Electrophysiology systems
  • Surgical ablation clamps
  • Thyroid nodule ablation

Where Pulse Biosciences is headquartered

Location

Headquarters

HQ city
Hayward
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pulse Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. nPulse/Vybrance System Sales: Revenue generated from sale of nPulse ablation systems including consoles, catheters, and electrodes to healthcare providers and hospitals for clinical procedures and trials.
  2. Clinical Procedure Revenue: Revenue from medical procedures using nPulse technology at treatment centers. Q1 2026 reported $401,000 in revenue; Q4 2025 reported $264,000 primarily from Vybrance systems and electrodes.
  3. At-the-Market Equity Offerings: Company raises capital through at-the-market equity offering programs. In May 2026, co-chairmen purchased $13.3 million of company stock through the ATM program managed by TD Securities.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Pulse Biosciences product offering

Product offering

Core offering

Pulse Biosciences develops and commercializes medical devices based on its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. The company sells the FDA-cleared nPulse Vybrance Percutaneous Electrode System for soft tissue ablation and is developing investigational devices—the nsPFA 360 Catheter Endocardial Ablation System and the nsPFA Cardiac Surgical Clamp—for treating atrial fibrillation through catheter-based and open surgical approaches. All systems rely on a shared nsPFA Console generator that delivers nanosecond electrical pulses to induce regulated cell death while sparing noncellular tissue.

Product overview

Pulse Biosciences offers a platform-based product portfolio built around its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. The nPulse Vybrance Percutaneous Electrode System is FDA-cleared for soft tissue ablation in percutaneous and intraoperative procedures. The nsPFA 360 Catheter Endocardial Ablation System and nsPFA Cardiac Surgery Ablation System (nPulse Cardiac Clamp) are investigational devices for treating atrial fibrillation through catheter-based and surgical approaches respectively. All cardiac products share the nsPFA Console as the common generator platform, which delivers the underlying nanosecond pulsed field energy that enables cell-targeting ablation while sparing adjacent noncellular tissue structures.

Differentiator

Problem solved

Functional benefit

Brands

  • CellFX: Brand name for the company's nsPFA technology platform used for cardiac applications.
  • nPulse Vybrance
  • nsPFA 360 Catheter
  • nsPFA Cardiac Clamp

Products and services

  • nPulse Vybrance Percutaneous Electrode System FDA-cleared percutaneous electrode system utilizing Nanosecond Pulsed Field Ablation (nsPFA) energy for ablation of soft tissue in percutaneous and intraoperative surgical procedures. It induces regulated cell death while sparing adjacent acellular tissue including vessels, nerves, and connective tissue, used for benign thyroid nodule ablation.
  • nsPFA 360 Catheter Endocardial Ablation System Investigational cardiac catheter system for endocardial ablation during electrophysiology procedures, comprising the nsPFA Console and nsPFA 360 Catheter with integrated sensing electrodes, designed to create circumferential ablation for pulmonary vein isolation while sparing acellular tissue in atrial fibrillation treatment.
  • nsPFA Cardiac Surgery Ablation System (nPulse Cardiac Clamp) Investigational cardiac surgical clamp system using nsPFA technology for ablation during open concomitant surgical atrial fibrillation procedures. Available in 53mm or 65mm jaw lengths, designed to create continuous linear transmural ablations while minimizing damage to surrounding acellular tissue.
  • nsPFA Console (Generator Platform) Power generator platform that delivers Nanosecond Pulsed Field Ablation energy for the nPulse product family. Operated via integrated touch screen and foot pedal, the console generates nanosecond PFA energy designed to induce regulated cell death of treated cardiac tissue while shielding interconnected lab equipment.

Quantifiable outcome

  • 96% procedural success at 12 months follow-up for atrial fibrillation treatment
  • +6 more outcomes

Companies that use Pulse Biosciences

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Pulse Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature6 records

Pulse Biosciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development Partner · 9 December 2025Research collaboration to evaluate nPulse technology for treating thyroid cancers, with planned clinical study for papillary thyroid microcarcinoma treatment beginning early 2026. Preclinical studies on anaplastic thyroid carcinoma are ongoing. This collaboration extends the nsPFA platform into oncology applications.
  • AbbottcoreTechnology or IntegrationnPulse Cardiac Catheter System is integrated with Abbott's EnSite X 3D electroanatomical mapping system for pulmonary vein isolation procedures. Integration enables procedural workflow combining nPulse ablation with Abbott's mapping technology.
  • Johnson & Johnson (Biosense Webster)coreTechnology or IntegrationnsPFA 360 Catheter integrated with CARTO 3 Mapping System from Johnson & Johnson for live case demonstrations at HRS 2025. Integration enables combined ablation and mapping workflow for atrial fibrillation procedures.

Scale indicators11 records

Recent moves6 records

Expansion highlights7 records

Pulse Biosciences competitors and assessment

Company assessment

Direct peers

  • Boston Scientific: Boston Scientific's FARAPULSE pulsed field ablation system is the leading commercial PFA catheter for atrial fibrillation, directly competing with Pulse Biosciences' nPulse 360 Catheter in the same EP lab workflow and AF indication.
  • Johnson & Johnson (Biosense Webster): Biosense Webster's CARTO 3 mapping and ThermoCool/Smart-Touch PFA catheters compete directly in AF ablation, and Pulse Biosciences' catheter is already integrated with CARTO 3, making J&J both a partner and a direct competitor.
  • Abbott: Abbott's EnSite X mapping system and TactiFlex PFA catheter compete in EP ablation; Pulse Biosciences integrates with EnSite X, positioning Abbott as both a workflow partner and competitive incumbent.
  • Medtronic: Medtronic's PulseSelect and Affera-derived PFA systems target the same AF ablation market as Pulse Biosciences' nPulse 360, with a deep EP installed base and global commercial reach.
  • AtriCure: AtriCure is the dominant player in surgical AF ablation (the Isolator Synergy clamp and cryo devices) and is the closest direct competitor to Pulse Biosciences' nsPFA Cardiac Clamp in the open concomitant surgical AF setting.
  • AngioDynamics: AngioDynamics markets the NanoKnife irreversible electroporation system, the closest direct mechanistic peer to nsPFA, used for soft tissue ablation including prostate and pancreatic lesions, with overlap on the Vybrance non-cardiac indication.

Emerging players

  • Galvanize Therapeutics: Galvanize Therapeutics is a private pulsed electric field company developing EP and oncology ablation platforms, intersecting with both Pulse's cardiac catheter and soft tissue/oncology roadmaps as an emerging PFA competitor.
  • Adagio Medical: Adagio Medical develops a cryo-PFA hybrid catheter for AF ablation, positioning it as a partial-overlap emerging competitor to Pulse's nPulse 360 in the paroxysmal and persistent AF EP market.
  • Penumbra: Penumbra has expanded from thrombectomy into the electrophysiology and PFA space through Lightning Flash and related catheter platforms, creating indirect competition with Pulse's cardiac ablation program.

Regional players

  • MicroPort Scientific: MicroPort's EP division (formerly Cardiac Rhythmic Technologies and acquired assets) markets cardiac ablation products in Asia and Europe, representing a regional PFA/AF ablation competitor to Pulse's eventual global rollout.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Pulse Biosciences social profiles

Digital presence

Pulse Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pulse Biosciences leadership team

Management profile

Number of profiles

Profiles13 records

Pulse Biosciences funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pulse Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pulse Biosciences

What does Pulse Biosciences do?

Pulse Biosciences develops and commercializes medical devices based on its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. The company sells the FDA-cleared nPulse Vybrance Percutaneous Electrode System for soft tissue ablation and is developing investigational devices—the nsPFA 360 Catheter Endocardial Ablation System and the nsPFA Cardiac Surgical Clamp—for treating atrial fibrillation through catheter-based and open surgical approaches. All systems rely on a shared nsPFA Console generator that delivers nanosecond electrical pulses to induce regulated cell death while sparing noncellular tissue.

Is Pulse Biosciences a public or private company?

Pulse Biosciences is a public company. It is classified as public and is currently operating.

When was Pulse Biosciences founded?

Pulse Biosciences was founded in 2014. It employs 101 to 250 people.

Where is Pulse Biosciences based?

Pulse Biosciences is headquartered in Hayward, United States, in the North America region.

How does Pulse Biosciences make money?

Three revenue lines are on record. nPulse/Vybrance System Sales are the primary driver. The others are clinical Procedure Revenue and at-the-Market Equity Offerings.

Who are Pulse Biosciences's main competitors?

Direct peers on record are Boston Scientific, Johnson & Johnson (Biosense Webster), Abbott, Medtronic, AtriCure and AngioDynamics. Emerging players are Galvanize Therapeutics, Adagio Medical and Penumbra. MicroPort Scientific is listed as a regional player.

Does Pulse Biosciences have an API?

No public API is recorded for Pulse Biosciences.

What industry is Pulse Biosciences in?

Pulse Biosciences's product category is Cardiac Ablation Medical Devices. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StPulse Biosciences (PLSE) Stock Looks Overvalued Even With Clinical ProgressPulse Biosciences stock trades at $52.25, a 7x gain over three years, with a price-to-book ratio of 20.9x versus 2.5x for the industry. Early completion of the NANOPULSE-AF study and CE Mark progress may support commercialization, but the valuation remains overvalued on book value.Investing.comPulse Biosciences at stifel 2026 healthcare conference: afib push buildsPulse Biosciences presented its nanosecond pulsed field ablation platform at the Stifel 2026 Healthcare Conference, citing strong clinical results from a 150-patient feasibility study. The company reported 100% freedom from atrial fibrillation off drugs at six months and 96% at 12 months, with FDA approval expected in early 2028. It also outlined a regulatory path and a $4 billion atrial fibrillation market opportunity.Simply Wall StPulse Biosciences (PLSE) On Thyroid Data And Losses Has An Undervalued NarrativePulse Biosciences reported a net loss in Q3 2026 and released six-month PRECISE-BTN thyroid nodule data. Its shares surged over 330% year to date, with a recent one-day move to $58.17. Analysts see the stock as undervalued, but a DCF model suggests a fair value of $16.19.Defense WorldPulse Biosciences (NASDAQ:PLSE) Rating Lowered to Sell at Wall Street ZenWall Street Zen downgraded Pulse Biosciences to a Sell rating, while other firms like BTIG, Needham, and Canaccord gave Buy ratings. The stock opened at $53.29, with an average rating of Moderate Buy and a price target of $66.60. The company reported a loss of $0.32 per share, missing estimates.American Banking and Market NewsPulse Biosciences (NASDAQ:PLSE) Price Target Raised to $74.00Canaccord Genuity raised its price target on Pulse Biosciences to $74.00 from $58.00, keeping a buy rating. The stock opened at $53.29, with a consensus rating of Moderate Buy and an average target of $66.60. The company reported a loss of $0.32 per share for the quarter, missing estimates.Defense WorldNeedham & Company LLC Forecasts Strong Price Appreciation for Pulse Biosciences (NASDAQ:PLSE) StockNeedham & Company raised its price target on Pulse Biosciences to $64 from $58, keeping a buy rating. The consensus price target is $66.60, with an average rating of Moderate Buy. The stock opened at $53.29 on Friday.YahooPulse Biosciences Inc (PLSE) Q3 2026 Earnings Call Highlights: NanoPulse AF Study Enrollment ...Pulse Biosciences completed enrollment in its NanoPulse AF pivotal IDE study in under six months with 169 evaluable patients. The company reported a GAAP net loss of $23.1 million and $189 million in cash, with European feasibility data showing 96% freedom from AF at one year. It expects spending to rise as it moves into additional clinical studies.TradingViewNeedham maintains Pulse Biosciences at Buy, raises price target to $64 from $58Needham maintained Pulse Biosciences at Buy and raised its price target to $64 from $58, a 10.3% increase. The target implies a 20.6% upside from the Nov 5 close of $53.07.Investing.comMizuho raises Pulse Biosciences stock price target on trial progressMizuho raised its price target on Pulse Biosciences to $65 from $55, citing faster-than-scheduled enrollment in the NANOPULSE-AF U.S. IDE study. The firm expects a U.S. launch in early 2028, with NANOCLAMP-AF enrollment completion in the first half of 2027. The stock has surged 287% year-to-date, trading at $53.07.YahooPulse Biosciences, Inc (PLSE) Reports Q3 Loss, Misses Revenue EstimatesPulse Biosciences reported a Q3 loss of $0.32 per share, beating the consensus estimate of $0.35, but revenue of $0.4 million fell 21% short of the $0.5 million estimate. The company has missed revenue estimates once in the past four quarters, and its Zacks Rank is Hold.